Related Experiment Video
Updated: Sep 24, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from
Günther Silbernagel1, Kévin Duarte2, Samir Sadiku3
1Division of Angiology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Insights
Statin treatment did not prevent cardiovascular events in hemodialysis patients. High cholesterol absorption increases cardiovascular risk, but statin therapy does not benefit patients with high cholesterol absorption.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Cardiovascular disease (CVD) is a leading cause of mortality in patients undergoing hemodialysis.
- Previous studies suggested statin therapy might reduce CVD risk in this population, but results have been inconsistent.
- Cholesterol metabolism, including absorption and synthesis, plays a role in CVD pathogenesis.
Purpose of the Study:
- To investigate the association between cholesterol absorption and synthesis rates and cardiovascular event risk in hemodialysis patients.
- To determine if cholesterol metabolism markers predict response to statin therapy in this population.
Main Methods:
- The AURORA trial was a randomized, double-blind, placebo-controlled study involving hemodialysis patients.
- Participants received rosuvastatin or placebo, with follow-up for cardiovascular death.
- Cholesterol absorption and synthesis were estimated using cholestanol and lathosterol to cholesterol ratios, respectively.
Main Results:
- High cholesterol absorption, indicated by higher cholestanol to cholesterol ratio, was significantly associated with increased cardiovascular death risk.
- High cholesterol synthesis, indicated by higher lathosterol to cholesterol ratio, was significantly associated with decreased cardiovascular death risk.
- No significant interaction was found between cholesterol metabolism markers and statin treatment in predicting cardiovascular death.
Conclusions:
- High cholesterol absorption is linked to elevated cardiovascular risk in hemodialysis patients.
- The findings do not support using cholesterol absorption rates to guide statin initiation in this patient group.
Aims:
Statin treatment did not reduce the risk of cardiovascular events in haemodialysis patients in the 4D and AURORA trials. Post hoc analyses in the 4D study suggested that high cholesterol absorption was associated with increased cardiovascular risk and that atorvastatin would reduce cardiovascular risk in haemodialysis patients with low cholesterol absorption but not in those with high cholesterol absorption.
Methods And Results:
AURORA is a randomized, double-blind, placebo-controlled, multi-centre trial in haemodialysis patients. The participants were randomly assigned to receive either rosuvastatin, 10 mg daily, or a matching placebo. There was a follow-up for cardiovascular death with a median duration of 3.9 years. The cholestanol and lathosterol to cholesterol ratios were used to estimate cholesterol absorption and synthesis, respectively. Measurement of non-cholesterol sterols was available in 2332 participants of the 2733 patients included in the primary analysis of the AURORA study. A total of 598 participants died from cardiovascular diseases. The 3rd vs. the 1st tertile of the cholestanol-to-cholesterol ratio was significantly associated with increased risk of cardiovascular death [hazard ratio, HR (95% confidence interval, CI) = 1.36 (1.11-1.65)] in univariate (P = 0.002) and multivariate models (P = 0.034). In contrast, the 3rd vs. the 1st tertile of the lathosterol-to-cholesterol ratio was significantly associated with decreased risk of cardiovascular death [HR (95% CI) = 0.81 (0.67-0.99)] in univariate (P = 0.041) and multivariate (P = 0.019) models. There was no significant interaction between the cholestanol and lathosterol to cholesterol tertiles and treatment group in predicting cardiovascular death.
Conclusion:
The present data from the AURORA study confirm that high cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients. Assessment of the individual cholesterol absorption rate to guide initiation of statin treatment is not supported by the findings in the AURORA study.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Hemodialysis II: Procedure and Complications
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Hemodialysis I: Introduction

